Both endothelin-1 (ET-1) and cAMP are implicated for inducing insulin resistance. Since we have shown previously that there is a crosstalk between ET-1 and cAMP signaling pathways in regulating glucose uptake in 3T3-L1 adipocytes, we extended our investigation in this study on whether they may have a synergistic effect on inducing insulin resistance. Our results showed that it was indeed the case. Insulin-stimulated glucose uptake, phosphorylation of PKB, IRS-1-associated PI3K, and IRS-1 tyrosine phosphorylation were all inhibited by ET-1 and 8-bromo cAMP in a synergistic manner. IRS-1 protein levels were similarly decreased by ET-1 and 8-bromo cAMP, attributable to suppressed mRNA expression. In addition, after correction for the loss in IRS-1 protein, the inhibition of insulin-stimulated IRS-1 tyrosine phosphorylation or IRS-1-associated PI3K was mainly caused by cAMP. Moreover, whereas IRS-2 protein levels were increased by cAMP or ET-1 plus cAMP, insulin-stimulated IRS-2-associated PI3K activities were abolished by both treatments. Furthermore, ET-1 and β-adrenergic agonists had similar synergistic inhibition on insulin-stimulated glucose uptake. In conclusion, we have shown that ET-1 and cAMP may synergistically induce insulin resistance in adipocytes via inhibiting IRS-1 expression as well as insulin-stimulated IRS-1/IRS-2 activities.
Introduction
ET-1 is a 21-amino acid polypeptide mainly secreted by endothelial cells. Besides being a potent vasoconstrictor [1] , ET-1 is closely related to insulin resistance. Elevated plasma concentrations of ET-1 has been reported in diabetes mellitus [2] , essential hypertension [3] , aging [4] , uremia [5] , post-surgery [6] , and obesity [7] , all of which are known to be accompanied by insulin resistance [8] [9] [10] [11] [12] [13] . Indeed, ET-1 was shown to induce insulin resistance in humans and rats [14] [15] [16] and inhibit insulin-stimulated glucose uptake in muscle cells [17] and adipocytes [18, 19] .
β-Adrenergic agonists have been well known for impairing insulin action and their inhibitory effects seem to be mediated by the signaling messenger cAMP [20] [21] [22] [23] . In concord, glucagon and parathyroid hormone (PTH) have also been shown to inhibit insulin-stimulated glucose transport via cAMP [24, 25] . Thus it appears that elevated cAMP may be one of the factors which induce insulin resistance.
We have shown previously that ET-1 and cAMP have a synergistic effect on GLUT1-mediated glucose uptake in 3T3-L1 adipocytes [26, 27] . In the present study, we further address the question if ET-1 and cAMP may have a synergistic effect on inducing insulin resistance. Using 3T3-L1 adipocytes as an insulin target, we show that ET-1 and cAMP indeed have a synergistic effect on inhibiting insulin-stimulated glucose uptake. The augmented inhibition seems to be attributable to decreased insulin-stimulated phosphorylation of protein kinase B (PKB) as a result of enhanced inhibition of insulin receptor substrate-1 (IRS-1) gene expression as well as inhibition of IRS-1/IRS-2 activities.
Materials and methods

Materials
fetal calf serum, glutamine, penicillin and streptomycin as described earlier [27] . Briefly, 2 days after confluence (day 0), the medium was removed and fresh medium containing 0.5 mM IBMX and 0.25 mM dexamethasone was added. After another 3 days, the medium was replaced with fresh culture medium and the cultures were then maintained as described above. By day 8, more than 90% of the cells have differentiated into rounded cells with lipid droplets. Day 8-12 differentiated 3T3-L1 adipocytes were used for experiments throughout this study.
Measurement of glucose transport activity
Glucose transport activity was analyzed by measuring uptake of [3H]2-deoxyglucose into the cells as described previously [28] . Carrier-specific uptake was obtained by correction for nonspecific diffusion of [3H]2-deoxyglucose into the cells as estimated in the presence of 10 μM cytochalasin B, which accounted for approx. 6-8% of the activity.
Preparation of cell lysates
After various treatments, cells were washed with phosphatebuffered saline (PBS) and lyzed in buffer containing 50 mM Tris, pH 7.4, 1 mM EDTA, 1 mM EGTA, 0.5 mM Na 3 VO 4 , 50 mM NaF, 5 mM Na 4 P 2 O 7 , 1 mM DTT, 10 mM β-glycerophosphate, 0.5% Nonidet P-40, 0.1 mM PMSF and protease inhibitor cocktail (Sigma) for 40 min on ice. After centrifugation at 20,000 ×g for 30 min at 4°C to remove the insoluble materials and the fat cake, the cell lysates were used for immunoprecipitation or immunoblot analysis.
Determination of tyrosine phosphorylation of IRS-1 and IRS-1-associated PI3K
Immunocomplex obtained from anti-IRS-1 antibody was used for the assessment of its tyrosine phosphorylation and associated p85, a subunit of PI3K. Briefly, after cell lysates were incubated with anti-IRS-1 for 8-12 h at 4°C, immunoprecipitates were collected by protein G-Magnetic Beads (Millipore), washed three times with PBS also containing 0.1% Tween 20, and subjected to immunoblot analysis with anti-IRS-1, anti-phosphotyrosine and anti-p85 antibodies.
Immunoblot analysis
After 7.5% SDS-polyacrylamide gel electrophoresis (PAGE) under reducing conditions as described earlier [29] , samples were transferred to a nitrocellulose membrane. The amount of specific protein on the membrane was then immunodetected by using appropriate primary and secondary antibodies. The blots were developed by the enhanced chemiluminescence method (ECL, Millipore). Quantification of relative band intensity was performed by laser scanning densitometry.
RNA preparation, RT-PCR and real-time PCR
Total cellular RNA was prepared using TRIzol reagent (Invitrogen) according to the manufacturer's instruction. cDNA synthesis was performed at 65°C using 2 μg of total RNA of 3T3-L1 adipocytes as the template primed with Oligo (dT)15. Aliquots of the cDNAs were subjected to PCR amplification using Platinum™ Tag DNA polymerase under optimal conditions in the presence of appropriate pairs of primers. IRS-1: (F) 5′-TGAACCTCAGTCCCAACCA-3′, (R) 5′-CAGCCACACATTCTCAAA GG-3′; IRS-2: (F) 5′-GTAGCCACAGGAGCAACACA-3′, (R) 5′-CAGGCGTG GTTAGGGAATAA-3′; and β-actin: (F) 5′-CATGTGCAAGGCCGGCTTCG CG-3′, (R) 5′-CTGGGTCATCTTCTCGCGGT-3′. The PCR products were analyzed by 2% agarose gel electrophoresis. For real-time PCR, cDNA was quantified using TaqMan® Gene Expression Assays (Product No. Mm00439720_s1 for IRS-1; Mm03038438_m1for IRS-2) (Applied Biosystems, Foster City, CA, USA).
Assay of IRS-2 associated PI3K activity
Immunocomplex obtained from anti-IRS-2 antibody was used for the assay of PI3K activity as described earlier [30] , using phosphatidylinositol and [γ-32 P]ATP as the substrates.
Statistical analysis
All experiments were performed for at least three times. The data are presented as means ± S.E. Statistical difference was determined by Student's t-test.
Results
Synergistic inhibition of insulin-stimulated glucose transport by prolonged treatment with ET-1 and cAMP
We showed previously that treatment of 3T3-L1 adipocytes with ET-1 and 8-bromo cAMP for 8 h only had a minor inhibitory effect on insulin-stimulated glucose uptake (↓13%, P N 0.05), although enhanced GLUT1 expression and GLUT1-mediated glucose transport tremendously [26] . To test the possibility that longer treatment with ET-1 and cAMP may be required to exert significant influence, we treated cell with ET-1 and 8-bromo cAMP for 12, 24, 36 and 48 h, and measured basal and insulin-stimulated glucose uptake. As shown in Fig. 1A & B, ET-1 alone increased glucose uptake to approximately 2.4-fold (P b 0.05) of basal and this enhancing effect lasted for at least 48 h, in accordance with our earlier finding that ET-1 enhanced glucose uptake by augmenting GLUT1 expression [31] . 8-Bromo cAMP alone had little influence on basal glucose uptake but it enhanced the stimulatory effect of ET-1 at 8 h and this enhancement declined with time, implying that the synergistic effect of ET-1 and cAMP on GLUT1-mediated glucose transport does not last for long period of time. On the other hand, while ET-1 alone had only a minor non-significant inhibitory influence on insulinstimulated glucose uptake (↓10-14%, P N 0.05, over the period of 48 h) and cAMP alone only exerted significant inhibitory effect at 48 h (↓30 ± 9%, P b 0.05), a combination of ET-1 and cAMP significantly inhibited insulin-stimulated glucose uptake and this inhibition was getting stronger with time (↓48 ± 11%, P b 0.02, ↓57 ± 11%, P b 0.02 and ↓70 ± 12%, P b 0.02 at 24, 36 and 48 h, respectively). The inhibitions by ET-1 plus cAMP at 24 and 36 h are significantly greater than the sum of inhibitions caused by ET-1 and cAMP alone (P b 0.05). Thus ET-1 and cAMP may exert a synergistic inhibition of insulin-stimulated glucose transport in a time-dependent manner.
Effect of ET-1 and cAMP on insulin-stimulated PKB phosphorylation
It is well known that insulin-stimulated glucose transport involves sequential events from activation of insulin receptor tyrosine kinase, tyrosine phosphorylation of IRS-1, activation of PI3-kinase, activation of PKB, and phosphorylation of AS160, to translocation of GLUT4 from intracellular compartments to plasma membranes [32] [33] [34] , and PKB seems to play a critical role in this process [35, 36] . To examine if PKB was inhibited by ET-1 and cAMP, we treated cells with ET-1, 8-bromo cAMP and both for 48 h and determined the insulin-stimulated phosphorylation of PKB at S473, an index of PKB activation [37] . As shown in Fig. 2A & B , whereas ET-1 alone had little effect, it significantly enhanced the inhibition caused by cAMP from 30 ± 7% (P b 0.05) to 61 ± 7% (P b 0.01). The extent of decrease in insulin-stimulated phosphorylation of PKB is comparable to that in insulin-stimulated glucose uptake in the presence of ET-1 and cAMP, suggesting that the inhibitory effect of ET-1 and cAMP should be exerted at PKB or its upstream signals.
Effect of ET-1 and cAMP on insulin receptor autophosphorylation
The initial event in insulin signaling pathway is the tyrosine phosphorylation of insulin receptor-β in response to insulin (autophosphorylation) [38] . To test the possibility that inhibition of insulin receptor autophosphorylation might be the primary effect of ET-1 and cAMP, 3T3-L1 adipocytes were treated with ET-1 + 8-bromo cAMP for 48 h, and analyzed for insulin-stimulated IR-β (Y1162/ 1163) phosphorylation as well as PKB phosphorylation. As shown in Fig. 3A , whereas ET-1 plus cAMP inhibited insulin-stimulated PKB phosphorylation, it actually increased insulin-stimulated insulin receptor phosphorylation. The increase in insulin receptor autophosphorylation most likely reflects the effect of ET-1 plus cAMP on enhancing the insulin receptor amount. Further investigation indicated that cAMP alone augmented insulin receptor amount; ET-1 had essentially no influence, either alone or in combination with cAMP ( Fig. 3B) . Thus it appears that the inhibitory effect of ET-1 and cAMP on insulin action should be some step downstream of insulin receptor autophosphorylation.
Effect of ET-1 and cAMP on insulin-stimulated tyrosine phosphorylation of IRS-1 and IRS-1-association with PI3K
Since IRS-1 is downstream of insulin receptor and upstream of PKB in insulin signaling cascades, and a well-known target for insulin resistance [34] , we treated cells with ET-1, 8-bromo cAMP and both for 48 h and determined their effects on insulin-stimulated tyrosine phosphorylation of IRS-1 and IRS-1-associated p85 (as an index for PI3K association). As shown in Fig. 4A & B, cAMP alone decreased total IRS-1 protein amount by 17 ± 5% (P b 0.05), and insulin-stimulated tyrosine phosphorylation of IRS-1 and IRS-1-associated PI3K by 43 ± 7% (P b 0.01) and 41 ± 6% (P b 0.01), respectively. On the other hand, whereas ET-1 alone had no significant influence, it potentiated the deteriorating effect of cAMP on IRS-1 protein content as well as insulin actions on IRS-1 tyrosine phosphorylation and IRS-1-associated p85. In the presence of both ET-1 and cAMP, IRS-1 protein content, insulinstimulated IRS-1 tyrosine phosphorylation and IRS-1-associated p85 were decreased by 64 ± 6% (P b 0.01), 76 ± 7% (P b 0.01) and 79 ± 10% (P b 0.01), respectively. To get a better evaluation of the effects of ET-1 and cAMP on insulin-stimulated tyrosine phosphorylation of IRS-1 and IRS-1-associated p85 per se, the data of Fig. 4B were re-plotted after correction for the amount of IRS-1 (Fig. 4C) . Regardless of the treatments, the extent of inhibition of insulin-stimulated tyrosine phosphorylation of IRS-1 is close to that of IRS-1-associated p85, indicating the correlation between these two events. Importantly, there is no significant difference between the inhibition caused by cAMP alone or by ET-1 plus cAMP, on insulin-stimulated IRS-1 tyrosine phosphorylation (36 ± 7% vs. 36 ± 6%) or IRS-1-associated p85 (33 ± 7%, vs. 41 ± 8%), implying that ET-1 has no potentiating effect on cAMP-evoked inhibition of insulin-stimulated IRS-1 tyrosine phosphorylation or IRS-1-associated PI3K. Similar results were obtained if immunoprecipitated p85 was used to estimate the formation of IRS-1/PI3K complex or tyrosine phosphorylation of IRS-1 ( Supplementary Fig. S1 ). Taken together, these results suggest that whereas cAMP decreases insulin-stimulated IRS-1 tyrosine phosphorylation, ET-1 plus cAMP has additional effect on reducing IRS-1 protein amount.
Time-dependent effect of ET-1 and cAMP on IRS-1 protein and mRNA levels
Given that the synergistic inhibition of insulin-stimulated glucose uptake is time-dependent (Fig. 1B) and the decrease in IRS-1 protein amount seems to play a major role in the presence of both ET-1 and cAMP, we measured time-dependent effect of ET-1 and 8-bromo cAMP on IRS-1 protein levels. As shown in Fig. 5A , while the effect of cAMP was relatively slow and to a much lesser extent (↓24 ± 7%, P b 0.05, at 48 h), ET-1 plus cAMP reduced IRS-1 protein amount at a faster pace and to a much greater extent. IRS-1 protein declined by approximately 25% (P b 0.02) at 12 h and 77 (P b 0.01) at 48 h. Since ET-1 alone had no significant effects (Figs. 1B & 4B) , the results indicate that the cooperation of ET-1 and cAMP facilitates the down-regulation of IRS-1 protein content, which plays an essential role in reducing insulin-stimulated glucose uptake.
Since IRS-1 protein is relatively stable (with a half-life of 10-14 h) [39, 40] and the decrease in IRS-1 protein abundance is rather slow in the presence of ET-1 and cAMP (see above), we further measured the time-dependent effect of ET-1 and cAMP on IRS-1 mRNA levels. As shown in Fig. 5B , while cAMP alone could reduce IRS-1 mRNA levels at a slow pace, ET-1 plus cAMP rapidly decreased IRS-1 mRNA to approximately 25% of control at 12 h and it remained gradually lower to approximately 10% of control at 48 h. Assuming that IRS-1 protein synthesis is tightly coupled to its mRNA levels, we estimate that in the presence of both ET-1 and cAMP, IRS-1 protein would degrade with a half-life of approximately 17 h, if all mRNA expression was terminated. This value is very close to that reported in the presence of transcription inhibitor actinomycin D [40] . Thus the decrease in IRS-1 protein levels can be reasonably accounted for by the strong inhibitory effect of ET-1 plus cAMP on IRS-1 mRNA expression.
Time-dependent effect of ET-1 and cAMP on IRS-2 protein and mRNA levels
In adipocytes, IRS-2 seems to partially compensate for impaired insulin action on IRS-1 [41] . Since IRS-2 expression was reported to be augmented by cAMP in pancreatic β-cell [42] , we determined IRS-2 expression in response to 8-bromo cAMP or ET-1 plus 8-bromo cAMP in 3T3-L1 adipocytes. As shown in Fig. 6A , cAMP increased IRS-2 protein amount in a time-dependent manner, reaching a plateau at 36-48 h. In accordance, IRS-2 mRNA levels were also enhanced by cAMP in a timedependent manner, reaching a peak at 36 h and declining thereafter (Fig. 6B) . Nevertheless, the increasing pace in IRS-2 protein levels was much faster than that in IRS-2 mRNA levels, implying that cAMP may exert its enhancing effect at both transcriptional and posttranscriptional levels. On the other hand, ET-1 does not seem to play any significant role in the regulation of IRS-2 expression, either alone (data not shown) or in combination with cAMP.
Inhibition of insulin-stimulated IRS-2-associated PI3K activity by cAMP
Both IRS-1 and IRS-2 are capable of transducing the insulin signal from activation of insulin receptor to downstream PKB [43] . The observation that IRS-2 protein levels are elevated by cAMP raises the issue whether the increased IRS-2 amount could help compensate for the loss in IRS-1 function? Nevertheless, the results from measuring IRS-2associated PI3K activities in cells treated with ET-1 and cAMP eliminate this possibility. As shown in Fig. 7 , while ET-1 alone had no influence, treatment with cAMP or ET-1 plus cAMP for 48 h abolished insulinstimulated IRS-2-associated PI3K activities. Therefore, although cAMP or ET-1 plus cAMP can augment IRS-2 protein amount, it does not help PKB activation in response to insulin, mainly due to the inhibition of IRS-2 function by cAMP.
Synergistic inhibition of insulin-stimulated glucose transport by ET-1 and β-adrenergic agonists
It is well known that β-adrenergic agonists exert their influence in adipocytes via a cAMP pathway [44] . The finding that ET-1 and cAMP had a synergistic interaction in inhibiting insulin-stimulated glucose transport prompted us to examine if the β-adrenergic agonists could act synergistically with ET-1 to inhibit insulin-stimulated glucose uptake. As shown in Fig. 8A & B , whereas epinephrine or norepinephrine Fig. 5A . The immunocomplex obtained with anti-IRS-2 antibody was used for the assay of PI3K activity as described in Materials and methods section and the product, phosphatidylinositol-3-32 P (PI3-P) was developed by thin layer chromatography on a Silica gel plate. Two other experiments showed similar results. alone had no significant effect on insulin action, both epinephrine and norepinephrine acted synergistically with ET-1 to inhibit insulin-stimulated glucose uptake by 66 ± 13% (P b 0.02) and 64 ± 9% (P b 0.01), respectively. Thus similar to ET-1 and cAMP, ET-1 and β-adrenergic agonists also induce a synergistic inhibition of insulin-stimulated glucose uptake. It further implies that there is a cross-talk between ET-1 and β-adrenergic signaling pathways in the regulation of insulin action in adipocytes.
Discussion
The major finding of this study is the synergistic inhibition of insulin action by ET-1 and β-adrenergic agonists (via cAMP) by a complex mechanism. It involves synergistic inhibition of IRS-1 expression by ET-1 and cAMP (the dominant effect) as well as the inhibition of IRS-1/IRS-2 activities by cAMP. Although the cAMP inhibition of IRS-1 function is rather mild (↓35%), insulin-stimulated IRS-2-associated PI3K activity is completely inhibited by cAMP. This inhibition of IRS-2 function by cAMP plays an essential role in the synergistic inhibition of insulin action by ET-1 and cAMP, since ET-1 plus cAMP dramatically increases IRS-2 expression by approximately 4-fold. Therefore, with cAMP inhibition of IRS-2 activity, the synergistic effect of ET-1 and cAMP on inhibiting insulin action becomes manifested.
At present, the mechanism of inhibiting IRS-1 expression by ET-1 and cAMP is unknown. Although the pivotal role of IRS-1 in insulin signaling and insulin resistance has been extensively investigated and established, relatively few studies regarding the regulation of IRS-1 gene expression have been reported. Dexamethasone [39] , PTH [25] , and adipocytokines [45] including IL-1β [46] , IL-6 and tumor necrosis factor-α (TNF-α) [47] have all been reported to down-regulate IRS-1 mRNA levels in adipocytes. Thus there exists a possibility that the effect of ET-1 plus cAMP could be indirectly mediated by released IL-1β, IL-6 or TNF-α. Since the release of IL-6 is synergistically induced by ET-1 and cAMP [48] , it would be of interest to test if IL-6 is involved in the synergistic inhibition of IRS-1 gene expression by ET-1 and cAMP.
On the other hand, IRS-1 promoter is subjected to both positive and negative regulation [49, 50] and contains many putative AP-1, Sp1 and AP-2β binding sites [51, 52] . While AP-2β [52] , ATRA [53] and BRCA1 [54] are implicated as negative regulators, AP-1 cooperating with SRC-3 [55] or Sp1 with estrogen receptor [51] seems to enhance the promoter activity. Thus the repressing effect of ET-1 plus cAMP on IRS-1 expression could potentially be exerted through potentiating the negative or inhibiting the positive regulatory factors. These possibilities are currently under investigation.
Besides adipocytes, adipose tissue contains blood vessels and is innervated by sympathetic nerves [56] . Accordingly, adipocytes in vivo are subjected to influences from ET-1 released from neighboring endothelial cells, norepinephrine released from nerve endings and circulating epinephrine. The finding in this study thus raises the possibility that under certain conditions whereas plasma levels of both ET-1 and catecholamines are sustainedly high, insulin action in adipocytes would be impaired and might lead to some diseases.
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